D. J. Waxman, J. L. Strominger (1983). Penicillin-binding proteins and the mechanism of action
ofβ-lactam antibiotics. Annu. Rev. Biochem. 52: 825–869.
M. P. Wentland, J. B. Comett (1985). Quinolone antibacterial agents. Annu. Rep. Med. Chem. 20:
145–154.
Antifungal Agents
J. Afeltra, P. E. Verweij (2003). Antifungal activity of nonantifungal drugs. Eur. J. Clin.
Microbiol. & Inf. Dis. 22: 397–407.
A. Albert (1985). Selective Toxicity, 7th ed. London: Chapman and Hall.
M. B. Anderson, T. Roemer, R. Fabrey (2003). Progress in anti-fungal drug discovery. Annu. Rep.
Med. Chem. 38: 163.
S. Arikan (2002). Lipid-based antifungal agents: a concise overview. Cell. & Mol. Biol. Lett.
7 : 919–922.
D. Berg, K. H. Büchel, M. Plempel, E. Regel (1986). Antimycotic sterol biosynthesis inhibitors.
Trends Pharmacol. Sci. 7: 233–238.
J. Como, W. Dismukes (1994). Oral azole drugs as antifungal therapy. New Engl. J. Med. 330: 263.
D. W. Denning (2003). Echinocandin antifungal drugs. Lancet 362: 1142–1151.
B. DiDomenico (1999). Novel antifungal drugs. Curr. Op. Microbiol. 2: 509–515.
M. B. Gravestock, J. F. Ryley (1984). Antifungal chemotherapy. Annu. Rep. Med. Chem. 19: 127–136.
R. Hay (1990). Fluconazole. J. Infect. 21:1.
C. Kauffman (1996). Role of azoles in antifungal therapy. Clin. Infect. Dis. 22: S148.
R. C. Matthews, J. P. Burnie (2004). Recombinant antibodies: a natural partner in combinatorial
antifungal therapy. Vaccine 22: 865–871.
C. P. Selitrennikoff, M. Nakata (2003). New cell wall targets for antifungal drugs. Curr. Opin.
Invest. Drugs 4: 200–205.
M. Viviani (1995). Flucytosine—What is the future? J. Antimicrob. Chemother. 35: 241.
A. Wong-Beringer, J. Kriengkauykiat (2003). Systemic antifungal therapy: new options, new
challenges.Pharmacotherapy 23: 1441–1462.
Antiparasitic Agents
K. L. Blair, J. L. Bennett, R. A. Pax (1992). Praziquantel: Physiological evidence for its site of
action in Schistosoma mansoni.Parisitology 104: 59.
I. Bruchhaus, E. Tannich (1993). Primary structure of the pyruvate phosphate dikinase in
Entoemeba histolytica. Mol. Biochem. Parisitol. 62: 153.
K. Chibale (2002). Towards broad spectrum antiprotozoal agents. ARKIVOC 9: 93–98.
R. N. Davidson (1998). Practical guide to the treatment of Leishmaniasis. Drugs 56: 1009.
C. Doerig (2004). Protein kinases as targets for anti-parasitic chemotherapy. Biochim. Biophys.
Acta 1697: 155–168.
J. E. Ellis (1994). Coenzyme Q homologs in parasitic protozoa as targets for chemotherapeutic
attack.Parisitol. Today 10: 296.
M. Foley, L. Tilley (1998). Quinoline antimalarials: Mechanisms of action. Pharmacol. Ther.
79 : 55.
O. Kayser, A. F. Kiderlen, S. L. Croft (2002). Natural products as potential antiparasitic drugs.
Stud. Nat. Prod. Chem. 26: 779–848.
H. O. Lobel, P. E. Kozarsky (1997). Update on the prevention of malaria. J. Amer. Med. Assoc.
278 : 1767.
598 MEDICINAL CHEMISTRY